BioSpace News Archive

To drive high quality patient data collection in clinical trials, YPrime, a global leader of Interactive Response Technology (IRT) and electronic Clinical Outcome Assessments (eCOA) today announced the release of its fourth-generation eCOA platform, which is designed to promote data integrity, accuracy and completeness through a featur

Armis Biopharma Inc. announced the launch of a new surface disinfectant called ArmiClenz™.

ERYTECH Pharma (Nasdaq & Euronext: ERYP),a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Gil BEYEN, Chief Executive Officer, will be participating in a fireside chat at the Jefferies Virtual Healthcare Conference on June 4, 2020, at 08:30 am ET.

Magellan Health, Inc. (NASDAQ: MGLN) today announced that its 2020 Annual Meeting of Stockholders (the “Annual Meeting”) has been changed to a virtual meeting format only.

Negative perceptions about emergency contraception are likely to hamper the sales of “morning after” pills in the future. Despite the high accessibility of emergency contraceptive pills, followed by rising awareness of highly-effective birth control methods, incidences of unwanted or mistimed pregnancies persist.

Surgical Information Sciences (SIS), a medical device company focused on improved visualization of targets for deep brain stimulation (DBS) surgery, announced completion of requirements to apply CE Mark to market its visualization capabilities in Europe.

Medcolcanna Organics Inc. (“Medcolcanna” or “the “Company”) (TSXV: MCCN) announces the filing of its annual financial and operating results for the year ended December 31, 2019 and for the three months ended March 31, 2020.

Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announces the preliminary results of a Phase 1 clinical study (NCT03545971) of the recombinant fully human anti-cytotoxic T-lymphocyte-associated antigen 4

The U.S. Food and Drug Administration continued to take action in the ongoing response to the COVID-19 pandemic

MedX Health Corp. (“MedX”) (TSX-V: MDX) announces that pursuant to the agreement for an online marketing and awareness program through AGORACOM, that was announced in the Press Release dated June 1, 2020, it has settled the first payment to AGORACOM, in the amount of 12,000 plus HST, or $13,560, by issuance on June 1, 2020, of 90,400 shares at an issue price of $0.15 per share.